Overview
- Tempus AI, which reported results Tuesday after the close, posted first‑quarter revenue of $348.1 million, up 36% year over year and above estimates.
- Shares dropped about 7% in extended trading after the company raised 2026 sales guidance to $1.59–$1.60 billion, a range that roughly matched Wall Street forecasts.
- Adjusted loss came in at $0.13 per share, but the GAAP net loss deepened to $125.9 million, driven by $56.3 million in stock‑based pay and $32.3 million in unrealized losses on securities.
- Operational growth stayed strong, with minimal residual disease blood tests that look for lingering cancer rising to about 6,500 in the quarter, roughly five times last year, and Data & Applications revenue up 40%.
- Management said no new financing is needed and projected better free cash flow in Q2, while analysts kept a Moderate Buy average target near $71 as recent insider sales added to investor focus on the path to profitability.